- Main
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
- Weber, Christopher J;
- Carrillo, Maria C;
- Jagust, William;
- Jack, Clifford R;
- Shaw, Leslie M;
- Trojanowski, John Q;
- Saykin, Andrew J;
- Beckett, Laurel A;
- Sur, Cyrille;
- Rao, Naren P;
- Mendez, Patricio Chrem;
- Black, Sandra E;
- Li, Kuncheng;
- Iwatsubo, Takeshi;
- Chang, Chiung‐Chih;
- Sosa, Ana Luisa;
- Rowe, Christopher C;
- Perrin, Richard J;
- Morris, John C;
- Healan, Amanda MB;
- Hall, Stephen E;
- Weiner, Michael W
Abstract
The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.